Boundless Bio, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 103.20% | -8.88% | -15.69% | -3.26% | 4.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.40% | -16.53% | -23.39% | -19.06% | -12.02% |
| Operating Income | -33.40% | 16.53% | 23.39% | 19.06% | 12.02% |
| Income Before Tax | -51.15% | 13.98% | 21.66% | 15.93% | 7.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.15% | 13.98% | 21.66% | 15.93% | 7.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.15% | 13.98% | 21.66% | 15.93% | 7.66% |
| EBIT | -33.40% | 16.53% | 23.39% | 19.06% | 12.02% |
| EBITDA | -28.42% | 16.64% | 23.84% | 19.59% | 12.45% |
| EPS Basic | -50.51% | 14.39% | 22.07% | 16.42% | 9.03% |
| Normalized Basic EPS | -40.21% | 14.38% | 22.07% | 16.43% | 9.05% |
| EPS Diluted | -50.51% | 14.39% | 22.07% | 16.42% | 9.03% |
| Normalized Diluted EPS | -40.21% | 14.38% | 22.07% | 16.43% | 9.05% |
| Average Basic Shares Outstanding | 0.42% | 0.48% | 0.52% | 0.59% | 1.51% |
| Average Diluted Shares Outstanding | 0.42% | 0.48% | 0.52% | 0.59% | 1.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |